Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Tandem Diabetes Care, Inc is a medical devices business based in the US. Tandem Diabetes Care shares (TNDM) are listed on the NASDAQ and all prices are listed in US Dollars. Tandem Diabetes Care employs 1,500 staff and has a trailing 12-month revenue of around USD$498.8 million.
|52-week range||USD$43.69 - USD$123.74|
|50-day moving average||USD$96.5542|
|200-day moving average||USD$102.4473|
|Wall St. target price||USD$127.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.96|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Tandem Diabetes Care stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Tandem Diabetes Care's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Tandem Diabetes Care's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$2.5 million.
The EBITDA is a measure of a Tandem Diabetes Care's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$498.8 million|
|Gross profit TTM||USD$260.5 million|
|Return on assets TTM||-0.95%|
|Return on equity TTM||-12.25%|
|Market capitalisation||USD$5.8 billion|
TTM: trailing 12 months
There are currently 3.9 million Tandem Diabetes Care shares held short by investors – that's known as Tandem Diabetes Care's "short interest". This figure is 3.8% up from 3.7 million last month.
There are a few different ways that this level of interest in shorting Tandem Diabetes Care shares can be evaluated.
Tandem Diabetes Care's "short interest ratio" (SIR) is the quantity of Tandem Diabetes Care shares currently shorted divided by the average quantity of Tandem Diabetes Care shares traded daily (recently around 595971.14197531). Tandem Diabetes Care's SIR currently stands at 6.48. In other words for every 100,000 Tandem Diabetes Care shares traded daily on the market, roughly 6480 shares are currently held short.
However Tandem Diabetes Care's short interest can also be evaluated against the total number of Tandem Diabetes Care shares, or, against the total number of tradable Tandem Diabetes Care shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Tandem Diabetes Care's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Tandem Diabetes Care shares in existence, roughly 60 shares are currently held short) or 0.0711% of the tradable shares (for every 100,000 tradable Tandem Diabetes Care shares, roughly 71 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Tandem Diabetes Care.
Find out more about how you can short Tandem Diabetes Care stock.
We're not expecting Tandem Diabetes Care to pay a dividend over the next 12 months.
Tandem Diabetes Care's shares were split on a 1:10 basis on 10 October 2017. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Tandem Diabetes Care shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Tandem Diabetes Care shares which in turn could have impacted Tandem Diabetes Care's share price.
Over the last 12 months, Tandem Diabetes Care's shares have ranged in value from as little as $43.69 up to $123.74. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tandem Diabetes Care's is 0.1601. This would suggest that Tandem Diabetes Care's shares are less volatile than average (for this exchange).
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin delivery system with Basal-IQ Technology; t:slim X2 with control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump and supported blood glucose meters for users, their caregivers, and their healthcare providers. Its products in development include t:sport insulin delivery system; and connected (mobile) health offerings. Further, the company offers Sugarmate, a mobile app for people with diabetes who use insulin. Tandem Diabetes Care, Inc. has a development and commercialization agreement with Dexcom, Inc. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was founded in 2006 and is headquartered in San Diego, California.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.